| Title |
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, August 2009
|
| DOI | 10.1007/s00280-009-1083-9 |
| Pubmed ID | |
| Authors |
Paul Haluska, Frank Worden, David Olmos, Donghua Yin, David Schteingart, Gretchen N. Batzel, M. Luisa Paccagnella, Johann S. de Bono, Antonio Gualberto, Gary D. Hammer |
| Abstract |
Insulin-like growth factor 1 receptor signaling through upregulation of the stimulatory ligand IGF-II has been implicated in the pathogenesis of adrenocortical carcinoma. As there is a paucity of effective therapies, this dose expansion cohort of a phase 1 study was undertaken to determine the safety, tolerability, pharmacokinetics, and effects on endocrine markers of figitumumab in patients with adrenocortical carcinoma. |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 2% |
| United States | 1 | 2% |
| China | 1 | 2% |
| Belgium | 1 | 2% |
| Unknown | 59 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 15 | 24% |
| Student > Bachelor | 13 | 21% |
| Researcher | 7 | 11% |
| Student > Doctoral Student | 6 | 10% |
| Student > Master | 5 | 8% |
| Other | 12 | 19% |
| Unknown | 5 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 51% |
| Agricultural and Biological Sciences | 7 | 11% |
| Biochemistry, Genetics and Molecular Biology | 5 | 8% |
| Nursing and Health Professions | 5 | 8% |
| Engineering | 2 | 3% |
| Other | 5 | 8% |
| Unknown | 7 | 11% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 January 2024.
All research outputs
#2,004,117
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#41
of 2,501 outputs
Outputs of similar age
#6,773
of 113,282 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#1
of 20 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 113,282 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.